Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Biology”), announced the Phase I clinical study data of SYS6002 monotherapy for the treatment of advanced cervical cancer in the form of a quick oral report at the 2026 International Society of Gynecological Oncology Global Meeting (IGCS Annual Global Meeting) held in Montreal, Canada from October 1 to October 3.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Biology”), announced the Phase I clinical study data of SYS6002 monotherapy for the treatment of advanced cervical cancer in the form of a quick oral report at the 2026 International Society of Gynecological Oncology Global Meeting (IGCS Annual Global Meeting) held in Montreal, Canada from October 1 to October 3.